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S_.manr Clinical outcome in ovarian carcinoma is predicted by progesterone receptor status, indicating an
endocrine aspect to this disease. Peripheral leucocyte genomic DNAs were obtained from 41 patients with
primary ovarian carcinoma and 83 controls from Ireland, as well as from 26 primary ovarian carcinoma
patients and 101 controls in Germany. Southern analysis using a human progesterone receptor (hPR) cDNA
probe identified a germline TaqI restriction fragment length polymorphism (RFLP) defined by two alleles: TI.
represented by a 2.7 kb fragment, and T2, represented by a 1.9 kb fragment and characterised by an additional
TaqI restriction site with respect to Ti. An over-representation of T2 in ovarian cancer patients compared with
controls in the pooled Irish German population (P<0.025) was observed. A difference (P<0.02) in the
distribution of the RFLP genotypes between Irish and German control populations was also observed. The
allele distributions could not be shown to differ significantly from Hardy-Weinberg distribution in any
subgroup. Using hPR cDNA region-specific probes, the extra TaqI restriction site was mapped to intron G of
the hPR gene.
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Ovarian cancer is the leading cause of death among patients
with gynaecological cancers with a 5 year survival rate,
averaged over all stages, of 29-32% (Scully, 1987). Such
high mortality is due largely to the insidious early progres-
sion of the disease and consequent detection at an advanced
tumour stage. The absence of a sufficiently specific and sen-
sitive screening test for diagnosis or prognosis of the disease
compounds the problem of its treatment.
Progesterone receptor estimation yields prognostic inform-
ation in ovarian carcinoma (Slotman et al., 1990; Chadha et
al., 1993; Noguchi et al., 1993), indicating a positive relation-
ship between progesterone receptor expression and prognosis.
The cDNA for the human progesterone receptor (hPR) was
first cloned and sequenced by Misrahi et al. (1987) and later
by Kastner et al. (1990). The structure of the hPR gene has
recently been described (Figure la) (Misrahi et al., 1993). The
presence of multiple forms of the hPR in ovarian carcinoma
has been reported (Scharl et al., 1991). Loss of heterozygosity
at the 1q23 locus in ovarian carcinoma has been reported
(Foulkes et al., 1993), indicating the presence in this region
of a tumour-suppressor gene relevant to ovarian carcinoma.
The hPR gene has been mapped by separate groups to the
1lq22-q23 locus (Rousseau-Merck et al., 1987; Mattei et al.,
1988). Transfection of an ovarian carcinoma cell line with
chromosome 11 has resulted in suppression of growth (Cao
et al., 1993), further suggestive of the presence of tumour-
suppressive regions on this chromosome.
Restriction fragment length polymorphisms (RFLPs) are
somatic or hereditary variations in the length of a DNA
fragment yielded by specific restriction endonuclease diges-
tion. Steroid hormone receptor gene RFLPs have been
previously studied in human female malignancies. A HindII
polymorphism in the progesterone receptor gene exhibited
non-Mendelian distribution in primary breast tumours
(Fuqua et al., 1991). A HindII polymorphism of the oest-
rogen receptor gene was found to correlate with progesterone
receptor expression in primary breast tumours (Wanless et
al., 1991). Furthermore, a specific pattern of differential
expression of the chicken ovalbumin upstream promoter
transcription factor (COUP-TF), an orphan of the steroid
hormone receptor superfamily, has been identified in human
ovarian cancer cell lines (Kieback et al., 1993), indicating the
possible role of this novel steroid receptor in ovarian car-
cinoma.
The TaqI restriction endonuclease recognition site TCGA,
containing all four base pairs found in DNA, allows analysis
of all 12 potential single base pair mutations (Sandy et al.,
1992). The presence in this recognition site of the di-
nucleotide sequence CpG is of particular importance given
that deamination of cytosine or 5-methylcytosine in CpG
dinucleotides is a common mechanism for the formation of C
to T transitions in cancer-related genes (Hollstein et al.,
1991). For these reasons, TaqI is especially useful in discern-
ing polymorphic alleles by RFLP analysis.
In order to investigate the status of the hPR gene in
primary ovarian carcinoma, we analysed peripheral leucocyte
genomic DNA from ovarian carcinoma patients and controls
for appearance of a germline TaqI RFLP in the hPR gene.
Material and methods
Polymerase chain reaction (PCR) and hPR cDNA
region-specific probes
Refer to Figure 1. Screening of a Agtl 1 random-primed T47D
human breast cancer cell line cDNA library with a 2 kb chick
oviduct progesterone receptor cDNA (both gifts from Dr
BW O'Malley, Baylor College of Medicine, Houston, TX,
USA) yielded a 1.85 kb cDNA, hPR-1, which was subse-
quently cloned in pGEM-4 (Promega, Madison, WI, USA)
using EcoRI to yield pGEM-4-hPR-I (Clifford-Brougham,
1989). The hPR-l cDNA (Figure Ib) consists of 1846 base
pairs (bp), of which 1084 bp represent 3' coding sequence and
the remaining 762 bp is 3'-untranslated sequence. hPR-l
probe was prepared for Southern analysis by digestion of
pGEM4-hPR-1 with EcoRI (Boehringer Mannheim), under
conditions specified by the manufacturer, and purified twice
by electroelution after separation on a 1% agarose electro-
phoresis gel. The hPR-2 cDNA probe (Figure 1c) was
generated by PCR using sense primer no. 1 (5'-TCGAGCTC-
Correspondence: DR Headon
*Present address: Department of Obstetrics and Gynaecology,
Baylor College of Medicine, Houston, Texas 77030, USA.
Received 22 September 1994; revised 31 October 1994; accepted I
November 1994x~~~~~~~Rgsmn eRF UinR num m --im Progssxerons r ep~ ~suw RRP NJ McKenna eta
452
ATG
7 1789 1906 2212 2357 2489 2646 2799
B-IC D E FT
E2 +-E J- E4 -f-E5 -1 E6 ~E7








Fue 1 (a) Structure of the human progesterone receptor (hPR) gene (Misrahi et al., 1993). Numbers above the exons (E -E8)
refer to cDNA base pair number (numbered from ATGI). T, location of TaqI cDNA restriction sites according to Kastner et al.
(1990). Introns (A-G) are represented by broken thin lines. The locations of the translation initiation (ATG) and translation
termination (TGA) codons are indicated. The hPR DNA-binding domain is encoded by exons 2 and 3. Exon 4 encodes the hinge
domain and part of the hormone-binding domain. Exons 5-8 encode the ainder of the hPR hormone-binding domain (Misrahi
et al., 1993). The cDNA probes used in Southern analysis (b) hPR-l, (c) hPR-2 and (d) hPR-3, are shown.
ACAGCGT`1TCTATCAA-3') corresponding to hPR cDNA
sequence 2593-2616 bp (numbered from ATGI), and the
antisense primer no. 2 (5'-AAAACCTACAAAACCCACAA-
TACT-3') (hPR cDNA sequence 3471-3494 bp, numbered
from ATG1) (Kastner et al., 1990). hPR-3 probe (Figure Id)
was generated by PCR amplification using the sense primer
no. 3 (5'-TCGACTTAAGAGAAAAAATCIl-lAC-3') (hPR
cDNA sequence 3133-3156 bp, numbered from ATG1)
(Kastner et al., 1990), and primer no. 2. Polymerase chain
reactions (PCRs) were carried out in a 100 ji1 final volume of
10mM Tnrs-H, 1.5mM magnesium chloride and 50mM
potassium chloride using 50 ng each of the oligonucleotide
primer pair, 100 ng of template pGem-4-hPR-I, 1.5 mM of
each dNTP and 2.5 units of Taq DNA polymerase (all PCR
reagents from Boehringer Mannheim). Each amplification
cycle (30 in total) consisted of a 90 s denaturation step at
94°C, a 90 s annealing step at 55°C and a 90 s extension step
at 72°C. PCR products were purified on a 1% low-melt
agarose gel (NuSieve GTG; FMC Bioproducts, Rockland,
ME, USA) before nick translation 32P-labelling.
DNA extraction, restriction enzyme digestion and Southern
blot analysis
Genomic DNA was isolated from whole human blood by a
modification of the method of Miller et al. (1988). Thawed
whole blood was incubated with an equal volume of 10 mM
Tris-HCI- 10 mM EDTA (pH 8.0) and centrifuged at 5000
r.p.m. for 10 min at 4°C. The supernatant was removed and
the pellet resuspended in 10mM Tris-HCI-lOmM EDTA
(pH 8.0) and centrifuged at 5000 r.p.m. for 10 min. The
supernatant was removed and the pellet washed in 1O mM
Tris-HCI- 10 mM EDTA (pH 8.0). After centrifugation at
5000 r.p.m. for 10 min at 4°C, the pellet was resuspended in
10mM Tris-HCI pH 8.0-5 mM EDTA-l% sodium dodecyl
sulphate (SDS)-0.4% Proteinase K (Sigma, St Louis, MO,
USA), incubated at 37TC overnight, and treated as described
previously (Miller et al., 1988). After spectrophotometric
determination of DNA concentration and purity, 20 Lg of
each DNA was digested to completion with 40 units of TaqI
(Boehringer Mannheim} in a volume of 300 l at 65'C over-
night under conditions specified by the manufacturer. The
digested DNA samples were fractionated on a 0.8% agarose
gel and following denaturation (1.5 M sodium chloride, 0.5 M
sodium hydroxide) and neutralisation (1.5 M sodium chloride,
0.5 M Tris pH 7.2, 0.001 M EDTA) DNA was transferred
from the gel in 20 x SSC (3 M sodium chloride, 0.3 M sodium
citrate) by capillary action to a 6 x SSC-soaked nylon mem-
brane (Boehringer Mannheim). After overnight transfer of
DNA, the membranes were washed in 2 x SSC and baked
for 2 h at 80°C. Low-melt agarose gel-purified probe was
32P-labelled uing Prime-A-Gene (Promega, Madison, WI,
USA) to a specific activity of 2 x 108 c.p.m. iLg-' Prehybri-
disation was carried out in 6 x SSC, 5 x Denhardt's solution
[0.02% bovine serum albumin, 0.02% polyvinylpyrollidone,
0.02% Ficoll (Pharmacia, Uppsala, Sweden)], 0.5% SDS and
100pg ml' denatured salmon sperm DNA at 65°C for 3h.
The membranes were incubated in hybridisation fluid (as
prehybridisation fluid, containing 5 x 106 c.p.m. 32P labelled
probe) at 65'C for 18-24 h. Membranes were washed to a
final stringency of 0.5 x SSC-0.5% SDS at 65°C. The mem-
branes were exposed to Kodak X-OMAT XAR-5 autoradio-
graphic film (Sigma, St Louis, MO, USA) at - 70°C with
intensifying screens for 48-72 h.
Statistical analysis
Comparison of the observed genotypic distribution of the
TaqI hPR alleles between subgroups was carried out, where
appropriate, using x2 analysis. Caculation of expected
genotypic frequencies was performed using the Hardy-Wein-
berg equation and these expected frequencies were compared
by x2 analysis, using Yates' correction for expected classes
less than 5, with the observed frequencies in each subgroup
(Ayala and Kiger, 1980).
Results
Characterisation ofTaqIpolymorphism
Figures 2-4 show representative Southern hybridisation
analyses of penrpheral leucocyte genomic DNA using TaqI as
the restriction enzyme and the region-specific cDNA
fragments hPR-1, hPR-2 and hPR-3 respectively as the pro-
bes (Figure lb-d). A single, two-allele polymorphism was
detected, comprising TI, represented by an estimated 2.7 kb
fragment, and T2, represented by an estimated 1.9 kb frag-
ment, and characterised by possession of an additional TaqI
restriction site with respect to TI. Three genotypes were
detected: 2.7 kb/2.7 kb, individuals homozygous for the TI
allele (Figure 2, lanes 1 and 2); 2.7 kb/i.9 kb, individuals
heterozygous for the TI and T2 alleles (Figure 2, lane 3); and
1.9 kb/i.9 kb individuals homozygous for the T2 allele
(Figure 3, lanes 1 and 2).
Localisation ofaditional TaqI restriction site
hPR cDNA region specific probes were used for a
preliminary localisation of the additional TaqI site in the
hPR gene. Figure 2 shows three TaqI-digested genomic DNA
samples probed with the hPR-1 cDNA probe (Figure lb).
The restriction fragment hybridisation pattern shows four
invariant bands at approximately 5.0, 4.2, 3.5 and 0.6 kb and
the two variant fragments at 2.7 kb and 1.9 kb. Figure 3
shows the autoradiographic pattern when the hPR-2 cDNA
probe (Figure Ic) was used. As shown, the 1.9 kb fragment
(a)[ El
T
TGA(representing the T2 alele) hybridised with the hPR-2 cDNA
probe, indicating the presence of the extra TaqI site 3' to
nucleotide position 2593 bp (numbered from ATGI). Figure
4 shows four TaqI-digested samples probed with the hPR-3
cDNA probe (Figure ld). As shown, neither the 2.7 kb nor
the 1.9 kb fragment was detectable by this probe: the 0.6 kb
fragment was detected, however, indicating that the addi-
5-0 Kr,
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Fuwe 2 Representative Southern analysis of TaqI-digested
genomic DNA hybridised with the hPR-1 cDNA probe. Lanes 1
and 2 contain samples homozygous for the 2.7 kb Ti allele. Lane
3 contains a sample heterozygous for the TI and T2 alleles.
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tional TaqI site lies 5' to 3133 bp (numbered from ATG1).
When the hPR-2 cDNA probe (Figure Ic) was used, the
1.9 kb fragment co-segregated with an inconsistently hybrid-
ising smaller fragment of 0.8-1.Okb, suggesting that the
latter fragment is composed of predominantly intron G
sequence and has limited sequence overlap with the hPR-2
cDNA probe compared with the 1.9 kb fragment. These data
are consistent with the location of an additional TaqI site in
intron G of the T2 hPR allele generating, upon TaqI diges-
tion, a 1.9 kb fragment which has extensive sequence overlap
with the hPR-2 cDNA probe, and a smaller fragment com-
posed of predominantly intron G sequence.
It is notable that the numbers of restriction fragments
hybridising to each of the three cDNA probes hPR-l, hPR-2
and hPR-3 are consistent with the location of the TaqI
cDNA restriction sites according to Kastner et al. (1990) in
the human progesterone receptor cDNA (Figure 1).
Allelic distribution andfrequency in ovarian cancerpatients
and controls
Significant differences in the distribution of TI and T2 alleles
were observed between the pooled German/Irish ovarian car-
cinoma cases and in the pooled controls (P<0.025) (Table
I). No significant difference could be demonstrated in the
distribution of the alleles between cases and controls in Ire-
land (P = 0.18). The frequency of the T2 allele could not be
shown to differ significantly (P>0.4) between the case
groups of both countries, but was significantly higher in the
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Fugwe 3 Representative autoradiographic pattern using the
hPR-2 cDNA fragment to probe TaqI-digested genomic DNA.
Three genotypes are evident: 2.7 kb/1.9 kb, individuals hetero-
zygous for the TI and T2 alleles (lanes 4, 5 and 7); 1.9 kb/1.9 kb,
individuals homozygous for (lanes I and 2); and 2.7 kb/
2.7 kb, individuals homozygous for TI (lane 6). Lane 3 was
empty.
1 2 3 4
Flge 4 Localisation of the additional TaqI site in the hPR
gene. Lanes 1-4 contain genomic DNA samples heterozygous for
the TI and T2 TaqI hPR alleles. The samples were hybridised
with the hPR-3 cDNA probe. Differences in band intensity are
due to variations in the amount of DNA loaded.
Table I Distribution and frequencies of the hPR gene TaqI alleles in pooled, Irish and German ovarian cancer case and control groups
Genotype
TiITi Ti/T2 T2112 T2frequencvf Group Subgroup na n Frequency (95% CI)' n Frequency (95% CI) n Frequency (95% CI) (95% CI)
Pooled Casesd 67 43 64 (52-75) 23 35 (24-47) 1 1 (0-4) 0.19 (0.12-0.25)
Controlsd 184 146 79 (73-85) 33 18 (13-23) 5 3 (0-5) 0.12 (0.09 0.14)
Irish Cases 41 26 63.5 (47-78) 15 36.5 (22-53) 0 0 (0-0) 0.18 (0.10-0.28)
Controls' 83 58 70 (60-80) 21 25.5 (16-34) 4 5 (1-9) 0.17 (0.12-0.23)
German Cases 26 17 65 (46-85) 8 31 (12-50) 1 4 (0-11) 0.19 (0.08-0.30)
Controls' 101 88 88 (80-93) 12 12 (5-18) 1 1 (0-3) 0.07 (0.03-0.1)
'Number of individuals. bNumbers in parentheses are 95% confidence intervals. 'Allele frequency based on Hardy-Weinberg equation, p2 + 2pq + q2 = 1, where p = frequency of allele TI and q = frequency of alkle T2 in a given subgroup. Hardy-Weinberg distributions were calculated from values ofp and q obtained. x2 analysis was then used to compare these expected distributions with those observed. All subgroups
followed the expected distribution. d-Genotypic distributions ofsubgroups with common superscripts differed significantly when compared by x2
analysis: dp<0.025, 'P<0.02.Pvogindum mmspi gm IIFP insimum-In ic
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(P<0.02). The distribution of the two alleles in each group
exhibited Mendelian distribution as predicted by the
Hardy-Weinberg equation, except in the pooled controls, in
which significant deviation from that predicted was ap-
proached (P<0.15).
Region-specific analysis of the hPR gene demonstrated the
presence of an ovarian carcinoma-associated germline RFLP
in intron G in the hormone-binding domain-encoding region
of the gene. The prsence of multiple forms of the pro-
gesterone receptor in ovarian carcinoma has been reported
(Scharl et al., 1991). Possible explanations include multipe
polyadenylation sites, differences in gene regulatory regions
or alternative intron splicing. It may be reasonably
speculated that the polymorphism we have localsed to intron
G of the hPR gene has consequences for the integrity of the
regulatory functions of the hormone-binding domain, pos-
sibly through premature termination of the progesterone
receptor mRNA transcript or other faults in the splicng
mechanism. Hormone binding and regulated transriptional
activation by the progesterone receptor are dependent upon
the presence of a complete, intact hormone-binding do
deletion of part of this region induces a total loss of
hormone-biding and the ability to activate transcription in
vitro (Dobson et al., 1989).
Although the precise nature of the polymorphim we have
identified is yet to be determined, another contngency is that
it is a neutral polymorphism co-segregating with other pro-
gesterone receptor gene aberrations as yet undetected, as has
been suggested in the case of an intron A polymorphism in
the oestrogen receptor gene in breast cancer (Yaich et al.,
1992).
The demonstration of the tumour-suppressive properties of
chromosome 11 in an ovarian cancer cell ine (Cao et al.,
1993) as well as loss of beterozygosity in ovarian carcinoma
(Foulkes et al., 1993) at the hPR gene locus 11q22-q23
(Rousseau-Merck et al., 1987; Mattei et al., 1988) raise the
question of a possible tumour-suppressive role for the hPR.
The 1lq22-q24 locus contains a tumour-suppsor gene
relevant to breast cancer (Stickland et al., 1992) and cervic
carcinoma (Hampton et al., 1994). Our data give credence to
the possibility of a tumour-suppressive role for the hPR gene
in ovarian carcnoma.
Consiring the hypothesis of Knudson (1971) that one
defective copy of a tumour-suppressive gene is inherited and
the other subject to a somatic mutation, the over-repres-
entation of the T1/I2 heterozygote in ovarian carcinoma
patients suggests a possible scenario: that these individuals
have inherited a defective copy of the hPR gene and that the
other is subject to a somatic mutation. Long-term prospec-
tive studies will be required to monitor the incidnce of
ovarian carcinoma in the control group, especially in those
individuals with the T2FT2 genotype.
Whereas the frequency of the T2 alele is similar in the
Irish ahd German case groups, the higher frequency of T2 in
the Irish controls led to a smaler difference in T2 frequency
between the Irish case and control groups, hence signnce
could not be established in this population in this study.
The fact that the distribution of the TaqI RFLP alleles
approaches sigificnt deviation from that predicted by the
Hardy-Weinberg equation (P<0.15) in the pooled controls
will require further investigation.
To conclude, the current data show an association between
a TaqI RFLP and incidence of ovarian carcinoma. This
polymorphism is associated with ovarian cancer at a germlne
leveL as opposed to the tumour level. Further work will
characterise its role in the development ofovarian carcnoma.
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